Circulating immune architecture across age, exposures and disease in ethnically diverse UK cohorts.
Authors:
- Daniela ZanottiDZDaniela Zanotti
- Giuditta ClericiGCGiuditta Clerici
- Stephen WattSWStephen Watt
- Edoardo GiacopuzziEGEdoardo Giacopuzzi
- Manuel Tardáguila SanchoMSManuel Tardáguila Sancho
- Alessandro RaveaneARAlessandro Raveane
- Arianna LandiniALArianna Landini
- Jan P. EngelmannJEJan P. Engelmann
- Matiss OzolsMOMatiss Ozols
- Beatrice CostaBCBeatrice Costa
Preprint
Abstract
Human immune composition reflects genetic background and cumulative life-course exposures, yet how these influences shape immune architecture across populations and disease remains poorly understood. Here we integrate single-cell transcriptomics, matched clinical haematology and electronic health records from 5,079 individuals of European, British-Pakistani and British-Bangladeshi ancestries to quantify 26 circulating immune cell types and 62 transcriptional states. We map immune compositional variation associated with age, sex, adiposity and smoking, revealing distinct patterns across adulthood and associations between modifiable exposures and advanced immune age. Across common diseases, immune compositional signatures converge on recurrent inflammatory myeloid, adaptive-memory and interferon programmes, whose expression varies with age and population context. Cardiovascular therapies are associated with selective shifts in disease-associated immune states. Immune composition further discriminates common cardiometabolic diseases and resolves patients into endotypes with distinct metabolic and clinical profiles. These findings establish circulating immune architecture as an integrative phenotype linking life-course exposures, population context and disease, providing a framework for precision population immunology.Funding Information
- Wellcome Trust (220540/Z/20/A)
- Chan Zuckerberg Foundation (2020-224316)
- British Heart Foundation (BHF) Cambridge Centre for Research Excellence (RE/18/1/34212)
- European Union (IMPACT (G.A.N.) 101201772)
- Innovative Medicines Initiative 2 Joint. Undertaking (JU) (101007873 (EU-IMI2 101007873))
- Helmholtz Association
- Deutsche Forschungsgemeinschaft (DFG) (452881907 (grant CRC TRR 338))
- European Union ERC, DeepCell (101054957)
- Italian Ministry of Economy and Finance
- Italian Ministry of University and Research
- Wellcome (WT102627)
- Wellcome (WT210561)
- Medical Research Council (UK) (M009017)
- Medical Research Council (UK) (MR/X009777/1)
- Medical Research Council (UK) (MR/X009920/1)
- Higher Education Funding Council for England Catalyst
- Barts Charity (845/1796)
- Health Data Research UK
- NHS National Institute for Health Research Clinical Research Network (North Thames)
- National Institute for Health and Care Research Barts Biomedical Research Centre (NIHR203330)
- Alnylam Pharmaceuticals
- Genomics PLC
- Life Sciences Industry Consortium of AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc.